Welcome to BioLegend’s one-of-a-kind advanced search. Search by any one of the single fields below or narrow down your searches by using multiple parameters. Looking for an anti-mouse NK cell antibody for IHC? Or looking for a FITC-conjugated antibody against a human marker for dendritic cells to use for flow cytometry? Only BioLegend’s advanced search can provide you with the best answers. If you have further questions, please contact our technical service team at 858-768-5801.
Use this document lookup tool to find Current Product Datasheets, Certificates of Analysis, or MSDS for any antibody products you have purchased from BioLegend.
Use the search box below to perform a site search of BioLegend.com powered by Google™.
The antibody was purified by affinity chromatography, and conjugated with biotin under optimal conditions. The solution is free of unconjugated biotin.
Concentration:
0.5 mg/ml
Storage & Handling:
The antibody solution should be stored undiluted at 4°C. Do not freeze.
Each lot of this antibody is quality control tested by ELISA assay. For use as an ELISA detection antibody, a concentration range of 0.25-1.0 µg/ml is recommended. To obtain a linear standard curve, serial dilutions of human GM-CSF protein ranging from 500 to 4 pg/ml are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.
COA:
Application Notes:
ELISA1-4 or ELISPOT3,4 Detection: The biotinylated BVD2-21C11 antibody is useful as a detection antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the purified BVD2-23B6 antibody (Cat. No. 502202/502204) as the capture antibody. Flow Cytometry: The fluorochrome-labeled BVD2-21C11 is useful for intracellular immnunofluorescent staining and flow cytometric analysis to identify GM-CSF-producing cells within mixed cell populations. To view the intracellular cytokine staining protocol, please visit www.biolegend.com and click on the support section. Neutralization: The BVD2-21C11 antibody can neutralize the bioactivity of natural or recombinant GM-CSF1. Additional reported applications (for the relevant formats) include: immunoprecipitation1, Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated frozen tissue sections5,6, and immunocytochemistry. Note: For testing human GM-CSF in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 432001 to 432006) are specially developed and recommended.
Application References:
1. Abrams J, et al. 1992. Immunol. Rev. 127:5. 2. Abrams J, et al. 1994. Eosinophils in Allergy and Inflammation. Marcel Dekker New York. p.133. 3. Bacchetta R, et al. 1990. J. Immunol. 144:902. 4. Kita H, et al. 1991. J. Exp. Med. 174:745. 5. Andersson U, et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag. 6. Andersson J, et al. 1994. Immunology 83:16.
Granulocyte/macrophage - colony stimulating factor (GM-CSF) is a hematopoietic factor that is produced by activated T cells, B cells, mast cells, macrophages, fibroblasts, and endothelial cells. In addition to supporting colony formation of granulocyte/macrophage progenitors, GM-CSF is a growth factor for erythroid, megakaryocyte, and eosinophil progenitors.
Heterodimer GM-CSFR α subunit (CDw116); β-subunit (CDw131) which is also shared with the IL-3 and IL-5 receptor α chains
Bioactivity/Activities:
Growth/development granulocyte/macrophage progenitors; differentiates myeloblasts/monoblasts; synergizes with Epo proliferation of erythroid/megakaryocytic progenitors
Antigen References:
1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego. 2. Demetri G, et al. 1991. Blood 78:2791. 3. Fan D, et al. 1991. In vivo 5:571. 4. Negrin R, et al. 1992. Adv. Pharmacol. 23:263.
*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/terms). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.
This data display is provided for general comparisons between formats. Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors. If you need assistance with selecting the best format contact our expert technical support team.
Biotin anti-human GM-CSF
PE anti-human GM-CSF
PMA-restimulated Th2 polarized human peripheral blood lymphocytes were surface stained with CD3 PE/Cy5 and intracellularly stained with BVD2-21C11 PE.
PerCP/Cy5.5 anti-human GM-CSF
PMA and ionomycin-stimulated Th2 polarized human peripheral blood lymphocytes were surface stained with CD3 FITC and intracellularly stained with GM-CSF (clone BVD2-21C11) PerCP/Cy5.5 (top) or rat IgG2a, κ PerCP/Cy5.5 isotype control (bottom).
APC anti-human GM-CSF
PMA and ionomycin-stimulated Th2 polarized human peripheral blood lymphocytes were surface stained with CD3 FITC and intracellularly stained with GM-CSF (clone BVD2-21C11) APC (top) or rat IgG2a, κ APC isotype control (bottom).
